Denovo Biopharma receives US FDA fast track designation for its liafensine for treating patients with treatment-resistant depression
Major Depressive Disorder News
Publication date: Oct 12, 2024 Denovos discovery of a novel pharmacogenomic biomarker, DGM4, presents a new era for liafensine, a first-in-class triple reuptake inhibitor. Over 30% patients with MDD do ... Read more